万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300482 万孚生物

已收盘 04-30 15:00:00

{"stockData":{"symbol":"300482","market":"SZ","secType":"STK","nameCN":"万孚生物","latestPrice":27.67,"timestamp":1714460583000,"preClose":26.66,"halted":0,"volume":9573935,"delay":0,"floatShares":333000000,"shares":472000000,"eps":1.0643,"marketStatus":"已收盘","marketStatusCode":5,"change":1.01,"latestTime":"04-30 15:00:00","open":26.76,"high":28.35,"low":26.76,"amount":266000000,"amplitude":0.0596,"askPrice":27.68,"askSize":42,"bidPrice":27.67,"bidSize":144,"shortable":0,"etf":0,"ttmEps":1.0643,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":26.66,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":29.33,"lowLimit":23.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":471966578,"pbRate":2.37,"roa":"--","roe":"4.5%","epsLYR":1.1,"committee":-0.257732,"marketValue":13059000000,"floatMarketCap":9207000000,"peRate":25.99831,"changeRate":0.0379,"turnoverRate":0.0288,"status":0},"requestUrl":"/m/hq/s/300482","defaultTab":"news","newsList":[{"id":"2430847866","title":"4月25日万孚生物现381.98万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2430847866","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430847866?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:33","pubTimestamp":1714034015,"startTime":"0","endTime":"0","summary":"证券之星消息，4月25日万孚生物发生大宗交易，交易数据如下：大宗交易成交价格26.9元，相对当日收盘价溢价0.26%，成交14.2万股，成交金额381.98万元，买方营业部为广发证券股份有限公司广州花城大道证券营业部，卖方营业部为中国银河证券股份有限公司佛山顺德容桂证券营业部。近三个月该股共发生1笔大宗交易，合计成交1420.0手，溢价成交1笔。截至2024年4月25日收盘，万孚生物报收于26.83元，下跌0.26%，换手率2.4%，成交量8.0万手，成交额2.16亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033228.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429733741","title":"信达证券：给予万孚生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429733741","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429733741?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:27","pubTimestamp":1713922049,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金,曹佳琳近期对万孚生物进行研究并发布了研究报告《盈利能力持续增强，多元化布局助力高质量增长》，本报告对万孚生物给出买入评级，当前股价为25.95元。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为28.53。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400018811.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429175848","title":"信达证券给予万孚生物买入评级，盈利能力持续增强，多元化布局助力高质量增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429175848","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2429175848?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:13","pubTimestamp":1713921221,"startTime":"0","endTime":"0","summary":"信达证券04月24日发布研报称，给予万孚生物（300482.SZ，最新价：25.73元）买入评级。评级理由主要包括：1）常规业务保持增长，盈利能力持续增强；2）加强研发布局，多元化的产品布局助力公司实现“有梯次、高质量”的增长。风险提示：市场开拓不及预期的风险；新产品研发、注册及认证风险；政策变动风险；市场竞争导致产品价格大幅下降的风险。AI点评：万孚生物近一个月获得1份券商研报关注。文章来源：每日经济新闻原标题：信达证券给予万孚生物买入评级，盈利能力持续增强，多元化布局助力高质量增长","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042409280987a85d35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042409280987a85d35&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429801121","title":"中国银河：给予万孚生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429801121","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429801121?lang=zh_cn&edition=full","pubTime":"2024-04-24 07:26","pubTimestamp":1713914792,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培近期对万孚生物进行研究并发布了研究报告《2023年年报及2024年一季报业绩点评：常规业务强劲增长，三联检在美获批进展超预期》，本报告对万孚生物给出买入评级，当前股价为25.73元。　　呼吸道三联检FDA EUA获批，有望持续贡献业绩增量。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为28.53。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012751.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429719902","title":"万孚生物（300482）2024年一季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2429719902","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429719902?lang=zh_cn&edition=full","pubTime":"2024-04-23 06:05","pubTimestamp":1713823513,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期万孚生物发布2024年一季报。根据财报显示，本报告期中万孚生物营收净利润同比双双增长，应收账款上升。截至本报告期末，公司营业总收入8.61亿元，同比上升3.54%，归母净利润2.18亿元，同比上升7.2%。在主营业务没有发生重大变化的情况下，公司报告期内的应收账款的变动表明公司的回款压力正在变坏。营收分析方面，公司最新一期年度报表的现金流为正，经营性现金流和利润稍微不匹配，问题不大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300009805.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429914003","title":"万孚生物最新公告：美国子公司呼吸道三联检产品获得美国FDA EUA授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2429914003","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429914003?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:28","pubTimestamp":1713774527,"startTime":"0","endTime":"0","summary":"万孚生物公告，美国子公司呼吸道三联检产品获得美国FDA的应急使用授权（EUA）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200016189.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429291436","title":"4月22日万孚生物涨15.34%，易方达大健康混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429291436","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429291436?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:24","pubTimestamp":1713774295,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日万孚生物涨15.34%，收盘报25.49元，换手率5.11%，成交量17.02万手，成交额4.19亿元。重仓万孚生物的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为易方达大健康混合。易方达大健康混合目前规模为8.28亿元，最新净值1.783，较上一交易日下跌0.39%，近一年上涨20.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200015920.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429916227","title":"万孚生物(300482.SZ)美国子公司呼吸道三联检产品获美国FDA EUA授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2429916227","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429916227?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:47","pubTimestamp":1713772031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万孚生物(300482.SZ)公告，公司美国全资子公司Wondfo USA Co.,Ltd近日收到美国食品药品监督管理局(简称“FDA”)通知，美国子公司的新型冠状病毒、甲型流感病毒及乙型流感病毒三联检测试剂盒WELLlife COVID-19/Influenza A&B Test获得FDA的应急使用授权(EUA)，预期用途为：针对呼吸道传染病症表现5天内的前鼻腔样本，定性检测和区分甲乙型流感病毒或新型冠状病毒。该产品属于Point of Care(POC)专业用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106420.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429960293","title":"医疗器械板块拉升 万孚生物涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429960293","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2429960293?lang=zh_cn&edition=full","pubTime":"2024-04-22 10:25","pubTimestamp":1713752700,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证券时报e公司讯，医疗器械板块拉升，截至发稿，万孚生物涨超12%，亚辉龙涨超8%，洁特生物、华大智造、健帆生物等跟涨。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-04-22/doc-inassmrc3447119.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-22/doc-inassmrc3447119.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429317934","title":"万孚生物2023年净利降59.26% 传染病检测产品营收减七成半","url":"https://stock-news.laohu8.com/highlight/detail?id=2429317934","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2429317934?lang=zh_cn&edition=full","pubTime":"2024-04-21 23:06","pubTimestamp":1713711960,"startTime":"0","endTime":"0","summary":"　　4月21日电 营收减半，净利降近六成，万孚生物2023年业绩大幅下滑。　　4月21日，万孚生物发布2023年年度报告。数据显示，2023年，万孚生物实现营业收入27.65亿元，同比减少51.33%；归属于上市公司股东的净利润4.88亿元，同比减少59.26%。截至2023年末，公司资产总额57.72亿元，比上年末减少8.40%。　　中新经纬注意到，这是万孚生物年度营业收入、净利润自2015年上市以来首度下滑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-21/doc-inasrkcp1702936.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-21/doc-inasrkcp1702936.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429998035","title":"万孚生物(300482.SZ)2024一季度营收、净利同比双增","url":"https://stock-news.laohu8.com/highlight/detail?id=2429998035","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429998035?lang=zh_cn&edition=full","pubTime":"2024-04-21 18:22","pubTimestamp":1713694920,"startTime":"0","endTime":"0","summary":"4月21日晚，万孚生物披露2023年年度报告及2024年一季报。报告显示，2023年，公司实现营业总收入27.65亿元，归属于上市公司股东的净利润4.88亿元。2024年一季度研发费用1.06亿元，同比增长11.80%。稳健发展的同时，万孚生物积极回报投资者，公司2023年度计划向全体股东每10股派现金4元（含税）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqxpt1924339.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqxpt1924339.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429981890","title":"万孚生物(300482.SZ)发2023年度业绩，净利润4.88亿元，同比减少59.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429981890","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2429981890?lang=zh_cn&edition=full","pubTime":"2024-04-21 16:40","pubTimestamp":1713688800,"startTime":"0","endTime":"0","summary":"转自：金融界本文源自:金融界AI电报万孚生物(300482.SZ)发布2023年年度报告，营业收入27.65亿元，同比减少51.33%。归属于上市公司股东的净利润4.88亿元，同比减少59.26%。归属于上市公司股东的扣除非经常性损益的净利润4.15亿元，同比减少62.46%。基本每股收益1.10元，向全体股东每10股派发现金红利4元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-04-21/doc-inasqtfu3038421.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-04-21/doc-inasqtfu3038421.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2409077128","title":"万孚生物(300482.SZ)：深耕海外二十二载，加速出海扩大全球市场份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2409077128","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2409077128?lang=zh_cn&edition=full","pubTime":"2024-02-05 12:18","pubTimestamp":1707106680,"startTime":"0","endTime":"0","summary":"万孚生物，作为国内POCT的龙头企业，自2002年起便积极布局海外市场，致力于将中国智造的医疗科技推向全球。截至2023年底，万孚生物拥有逾10个营销中心，超20个海外办事处，20余家国内外子公司，为全球150多个国家和地区客户提供产品解决方案和技术支持。深化海外“本地化”运营智通财经了解到，近年来，万孚生物进一步深化海外市场战略，将国际业务作为中长期发展的战略重心。在本地化生产方面，万孚生物采取了积极的措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-05/doc-inafyhch7829178.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-05/doc-inafyhch7829178.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2394292365","title":"万孚生物：拟5000万元参设产业基金 主要投资于生物与健康产业领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2394292365","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2394292365?lang=zh_cn&edition=full","pubTime":"2023-12-26 10:42","pubTimestamp":1703558558,"startTime":"0","endTime":"0","summary":"万孚生物（300482）公告称，为促进公司战略布局和长期资产配置，公司作为有限合伙人拟与广州三美投资管理中心（有限合伙）等共同投资设立广州三美二期医疗创业投资基金（有限合伙）（暂定名，以工商部门最终设立登记的名称为准），该基金主要投资于生物与健康产业领域。","market":"other","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/658a3e7453243c07837543ca","is_publish_highlight":false,"gpt_icon":0},{"id":"2394654296","title":"万孚生物(300482.SZ)拟5000万元参投三美二期基金 布局生物与健康产业领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2394654296","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2394654296?lang=zh_cn&edition=full","pubTime":"2023-12-26 08:13","pubTimestamp":1703549580,"startTime":"0","endTime":"0","summary":"万孚生物公告，公司作为有限合伙人拟与广州三美投资管理中心、广州市工业转型升级发展基金有限公司、广州市新兴产业发展基金管理有限公司、广州道明投资合伙企业、广州市海珠生命健康产业投资合伙企业和广州创新投资母基金合伙企业共同投资设立广州三美二期医疗创业投资基金。三美二期基金主要投资于生物与健康产业领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-26/doc-imzzhvsf2313511.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-26/doc-imzzhvsf2313511.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-30","address":"广东省广州市黄埔区科学城荔枝山路8号","stockEarnings":[{"period":"1week","weight":0.0754},{"period":"1month","weight":0.1248},{"period":"3month","weight":0.1481},{"period":"6month","weight":0.0651},{"period":"1year","weight":-0.0654},{"period":"ytd","weight":-0.0829}],"companyName":"广州万孚生物技术股份有限公司","boardCode":"AI0027","perCapita":"8017股","boardName":"医药制造业","registeredCapital":"47196万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　广州万孚生物技术股份有限公司专业从事快速诊断试剂及配套仪器的研发、制造、营销及服务，是国内POCT的龙头企业之一。主要有心脑血管疾病、炎症、肿瘤、传染病、毒检（药物滥用）、优生优育等检验领域的产品线。2019年，公司首次取得MDSAP证书，证明公司质量体系同时符合ISO13485:2016标准以及美国FDA、加拿大HC、澳大利亚TGA、巴西ANVISA四国监管要求。","serverTime":1714755678777,"listedPrice":16,"stockholders":"41501人(较上一季度减少5.20%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万孚生物,300482,万孚生物股票,万孚生物股票老虎,万孚生物股票老虎国际,万孚生物行情,万孚生物股票行情,万孚生物股价,万孚生物股市,万孚生物股票价格,万孚生物股票交易,万孚生物股票购买,万孚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}